Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PTOUF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LY4101174
|
|||||
| Synonyms |
LY4101174; ETx-22
Click to Show/Hide
|
|||||
| Organization |
Emergence Therapeutics (Top20 MNC) (Originator);Heidelberg Pharma (Originator) (No Rights);Mablink Bioscience (Top20 MNC) (No Rights)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-Nectin-4 antibody
|
Antibody Info | ||||
| Antigen Name |
Nectin-4 (NECTIN4)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
maleimide-β-glucuronide poly-sarcosine linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Cervical cancer |
1 Trials
|
||||||||
| Head and neck cancer |
1 Trials
|
||||||||
| Kidney cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Oesophageal cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Pancreatic cancer |
1 Trials
|
||||||||
| Prostate cancer |
1 Trials
|
||||||||
| Urothelial cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients have specified advanced solid tumors (urothelial, TNBC, NSCLC, etc.) with disease progression after prior therapies (requirements vary by cohort). Key requirements include ECOG 0-1, measurable disease (except Cohort A1), and available tumor tissue. Exclusion criteria include CNS metastases, uncontrolled comorbidities (hypercalcemia, diabetes), corneal disease, recent thromboembolic events, QTcF ≥470ms, or active infections.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06238479 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors | ||||
| Primary Endpoint |
The Phase 1a primary objective is to establish LY4101174's recommended dose based on dose-limiting toxicities (DLTs) observed within the first two 28-day cycles. Phase 1b evaluates antitumor activity through overall response rate (ORR) as per RECIST 1.1 criteria over approximately 4 years.
|
||||
| Other Endpoint |
Pharmacokinetic analysis assesses minimum plasma concentration (Cmin) and area under curve (AUC) during initial treatment cycles (56 days). Antitumor evaluation includes multiple efficacy measures: ORR, duration of response (DOR), time to response (TTR), progression-free survival (PFS), disease control rate (DCR) and overall survival (OS) - all assessed per RECIST 1.1 over ~4 years.
Click to Show/Hide
|
||||
References